ALTS-OP1 / Alteogen - LARVOL DELTA

Altos Bio, Dual Antibody Retinal Vascular Disease Treatment PCT Application [Google translation] (HIT News) - "Altos Biologics announced on the 4th that it has completed the PCT (Patent Cooperation Treaty) application for its dual antibody-based retinal vascular disease treatment drug, 'ALTS-OP1'...This is a measure to secure patent rights in major countries around the world, following the priority application last year...The company explained that ALTS-OP1 is a treatment for wet macular degeneration that simultaneously regulates the vascular endothelial growth factor (VEGF) and Tie2 pathways, and is expected to provide an effective treatment option compared to existing anti-VEGF single treatments....In addition, the company said that it confirmed through animal testing that the product has a superior effect in preventing leakage in a single layer of vascular endothelial cells (HUVEC) compared to Roche's Vabysmo. This PCT application reflects additional data acquired after the previous priority application." "

Patent • Preclinical • Retinal Disorders